Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol vs Sevoflurane in HCC Hepatectomy
NCT05331911Phase 4Recruiting
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of propofol injection (veterinary) in hepatocellular carcinoma (HCC) (2 arms), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoints: Overall Survival at 36 months and Disease Progression at 36 months. Started Apr 2022; status: recruiting.
02
Drugs
propofol injection (veterinary)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05331911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331911.